Novartis Raises FullYear Sales and Profit Guidance Signaling Strong Operational Momentum KRMD Q1 2026 Earnings Narrow EPS Beat Signals Steady Progress Amid Loss Reduction GigaIPOs Reflect a Growing Malaise in Public Markets The Economist Argues